These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 36725119)

  • 21. Is hematopoietic cell transplantation still a valid option for mantle cell lymphoma in first remission in the chemoimmunotherapy-era?
    Chaudhary L; Kharfan-Dabaja MA; Hari P; Hamadani M
    Bone Marrow Transplant; 2013 Nov; 48(12):1489-96. PubMed ID: 23584438
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ATM and TP53 mutations show mutual exclusivity but distinct clinical impact in mantle cell lymphoma patients.
    Mareckova A; Malcikova J; Tom N; Pal K; Radova L; Salek D; Janikova A; Moulis M; Smardova J; Kren L; Mayer J; Trbusek M
    Leuk Lymphoma; 2019 Jun; 60(6):1420-1428. PubMed ID: 30626249
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Complex analysis of the TP53 tumor suppressor in mantle cell and diffuse large B-cell lymphomas.
    Zlamalikova L; Moulis M; Ravcukova B; Liskova K; Malcikova J; Salek D; Jarkovsky J; Svitakova M; Hrabalkova R; Smarda J; Smardova J
    Oncol Rep; 2017 Oct; 38(4):2535-2542. PubMed ID: 28791403
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current Treatments in Mantle Cell Lymphoma.
    Avyakta Kallam Md ; Vose JM
    Oncology (Williston Park); 2023 Aug; 37(8):326-333. PubMed ID: 37616519
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Management of mantle cell lymphoma in the elderly: current and potential strategies.
    Vignon M; Venon MD; Hermine O; Delarue R
    Drugs Aging; 2013 Dec; 30(12):979-86. PubMed ID: 24178346
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study.
    Davids MS; Kim HT; Nicotra A; Savell A; Francoeur K; Hellman JM; Bazemore J; Miskin HP; Sportelli P; Stampleman L; Maegawa R; Rueter J; Boruchov AM; Arnason JE; Jacobson CA; Jacobsen ED; Fisher DC; Brown JR;
    Lancet Haematol; 2019 Jan; 6(1):e38-e47. PubMed ID: 30558987
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical outcome of Mantle Cell Lymphoma patients with high-risk disease (high-risk MIPI-c or high p53 expression).
    Scheubeck G; Jiang L; Hermine O; Kluin-Nelemans HC; Schmidt C; Unterhalt M; Rosenwald A; Klapper W; Evangelista A; Ladetto M; Jerkeman M; Ferrero S; Dreyling M; Hoster E
    Leukemia; 2023 Sep; 37(9):1887-1894. PubMed ID: 37495776
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic Role of CDKN2A Deletion and p53 Expression and Association With MIPIb in Mantle Cell Lymphoma.
    Gaudio F; Dicataldo M; Di Giovanni F; Cazzato G; d'Amati A; Perrone T; Masciopinto P; Laddaga FE; Musto P; Maiorano E; Ingravallo G
    Clin Lymphoma Myeloma Leuk; 2023 Aug; 23(8):599-605. PubMed ID: 37147150
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic heterogeneity and prognostic impact of recurrent ANK2 and TP53 mutations in mantle cell lymphoma: a multi-centre cohort study.
    Jeong S; Park YJ; Yun W; Lee ST; Choi JR; Suh C; Jo JC; Cha HJ; Jeong JY; Chang H; Cha YJ; Kim H; Park MJ; Song W; Cho EH; Jeong EG; Lee J; Park Y; Lee YS; Kim DJ; Lee HS
    Sci Rep; 2020 Aug; 10(1):13359. PubMed ID: 32770099
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network.
    Hermine O; Hoster E; Walewski J; Bosly A; Stilgenbauer S; Thieblemont C; Szymczyk M; Bouabdallah R; Kneba M; Hallek M; Salles G; Feugier P; Ribrag V; Birkmann J; Forstpointner R; Haioun C; Hänel M; Casasnovas RO; Finke J; Peter N; Bouabdallah K; Sebban C; Fischer T; Dührsen U; Metzner B; Maschmeyer G; Kanz L; Schmidt C; Delarue R; Brousse N; Klapper W; Macintyre E; Delfau-Larue MH; Pott C; Hiddemann W; Unterhalt M; Dreyling M;
    Lancet; 2016 Aug; 388(10044):565-75. PubMed ID: 27313086
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimal frontline management of mantle cell lymphoma: can we agree?
    Tang C; Kuruvilla J
    Expert Rev Hematol; 2018 Dec; 11(12):911-914. PubMed ID: 30336708
    [No Abstract]   [Full Text] [Related]  

  • 32. A Phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphoma.
    Dreyling M; Tam CS; Wang M; Smith SD; Ladetto M; Huang H; Novotny W; Co M; Romano A; Holmgren E; Huang J; Gouill SL
    Future Oncol; 2021 Jan; 17(3):255-262. PubMed ID: 32985902
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib.
    Jain P; Kanagal-Shamanna R; Zhang S; Ahmed M; Ghorab A; Zhang L; Ok CY; Li S; Hagemeister F; Zeng D; Gong T; Chen W; Badillo M; Nomie K; Fayad L; Medeiros LJ; Neelapu S; Fowler N; Romaguera J; Champlin R; Wang L; Wang ML
    Br J Haematol; 2018 Nov; 183(4):578-587. PubMed ID: 30175400
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New and emerging Bruton tyrosine kinase inhibitors for treating mantle cell lymphoma - where do they fit in?
    Rule S; Chen RW
    Expert Rev Hematol; 2018 Sep; 11(9):749-756. PubMed ID: 30052472
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mantle cell lymphoma: A clinical review of the changing treatment paradigms with the advent of novel therapies, and an insight into Indian data.
    Radhakrishnan VS; Lokireddy P; Parihar M; Prakash PS; Menon H
    Cancer Rep (Hoboken); 2022 Jul; 5(7):e1590. PubMed ID: 34821081
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mantle Cell Lymphoma: First-line Therapy in Patients Not Eligible for Stem Cell Transplantation.
    Nazeef M; Kahl BS
    Curr Treat Options Oncol; 2015 Jun; 16(6):29. PubMed ID: 25975443
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Exploiting PRMT5 as a target for combination therapy in mantle cell lymphoma characterized by frequent ATM and TP53 mutations.
    Che Y; Liu Y; Yao Y; Hill HA; Li Y; Cai Q; Yan F; Jain P; Wang W; Rui L; Wang M
    Blood Cancer J; 2023 Feb; 13(1):27. PubMed ID: 36797243
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gene mutations and actionable genetic lesions in mantle cell lymphoma.
    Ahmed M; Zhang L; Nomie K; Lam L; Wang M
    Oncotarget; 2016 Sep; 7(36):58638-58648. PubMed ID: 27449094
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluating real-world treatment patterns and outcomes of mantle cell lymphoma.
    Narkhede M; Goyal G; Shea L; Mehta A; Giri S
    Blood Adv; 2022 Jul; 6(14):4122-4131. PubMed ID: 35561314
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Overexpression of the key metabolic protein CPT1A defines mantle cell lymphoma patients with poor response to standard high-dose chemotherapy independent of MIPI and complement established highrisk factors.
    Gerdtsson AS; Matos Rodrigues J; Eskelund CW; Husby S; Grønbæk K; Räty R; Kolstad A; Geisler C; Porwit A; Jerkeman M; Ek S
    Haematologica; 2023 Apr; 108(4):1092-1104. PubMed ID: 36519324
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.